Email this article Rol' rituksimaba v lechenii nekhodzhkinskikh limfom(referativnyy obzor randomizirovannykh klinicheskikh issledovaniy)
- Authors: Mikhaylova NB1,2
-
Affiliations:
- Институт детской гематологии и трансплантологии им. Р.М.Горбачевой
- Санкт-Петербургский государственный медицинский университет им. И.П.Павлова
- Issue: Vol 11, No 3 (2009)
- Pages: 28-31
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26782
- ID: 26782
Cite item
Full Text
Abstract
За последние 30 лет благодаря стремительному развитию молекулярной генетики и иммунологии радикальным образом изменилось представление о биологиилимфопролиферативных заболеваний. Новые данные были отражены в менявших друг друга классификациях лимфом начиная с «морфологической» классификации Раппопорта и заканчивая классификацией ВОЗ 2008 г., учитывающей не только линейную принадлежность лимфомы (В-, Т- или НК- клеточную), но и ее генетические особенности. Полученные знания привели к созданию принципиально новых препаратов направленного или целевого (таргетного) воздействия на опухолевые клетки.
Full Text
##article.viewOnOriginalSite##About the authors
N B Mikhaylova
Институт детской гематологии и трансплантологии им. Р.М.Горбачевой;Санкт-Петербургский государственный медицинский университет им. И.П.Павлова
References
- Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus Rituximab compared with CVP as first - line treatment for advanced follicular lymphoma. Blood 2005;105: 1417–23.
- Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome for patients with advanced stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 2005; 106: 3725–32.
- Herold M, Pasold R, Srock S et al. Results of a prospective randomised open label phase III study comparing Rituximab plus Mitoxantrone, Chlorambucil, Prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin’s lymphoma (NHL) and mantle - cell - lymphoma(MCL).Blood 2004; 104: 584a.
- Salles G, Foussard C, Nicolas M et al. Rituximab added to aIFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: First analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood 2004; 104: 160a.
- Hiddemann W, Hoster E, Buske C et al. Rituximab is the essential treatment modality that underlies the significant improvement in short and long term outcome of patients with advanced stage follicular lymphoma – a 10 year analysis of GLSG trials. Blood; ASH Annual Meeting Abstracts, 2006: 108: Abstract 483.
- Schulz H, Bohlius J, Skoetz N et al. Combined immunochemotherapy with rituximab improves overall survival in patients with follicular and mantle cell lymphoma: updated meta - analysis results. Blood; ASH Annual. Meeting Abstracts, 2006: 108: Abstract 2760.
- Jack A, van t Veer M, Vranovsky A, Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non - Hodgkin’s lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood 2006;108, (10): 3295–301.
- Hochster H.S., Weller E, Ryan T et al. Results of E 1496: A phase III trial of CVPwith or without maintenance Rituximab in advanced indolent lymphoma (NHL).Proc Am Soc Clin Oncol 2004; 23: 556.
- Hagenbeek A, van Glabbeke M, Teodorovic I et al. The role of rituximab maintenance in relapsed follicular NHL: an interim analysis of the EORTC randomised intergroup trial [abstract]. Ann Oncol 2005;16: 52. Abstract 061.
- Forstpointner R., Unterhalt M. Dreyling M. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003.
- Dreyling M Forstpointner R, Boeck H-P et al. Combined immunochemotherapy followed by rituximab maintenance is an effective salvage treatment after prior rituximab containing therapy: results of a GLSG - subgroup analysis in patients with relapsed indolent lymphoma. Blood; ASH Annual Meeting Abstracts, 2006: 108: Abstract 2769.
- Coiffer B, Lepage E et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–42.
- Coiffer B, Feugier P, Mounier N et al. Long - term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older pAtients with diffuse large B-cell lymphoma show good survival in poor - risk patients/ J Clin Oncol 2007; 23: 2009.
- Pfreundschuh M, Trunmper L, Kloess M et al. Two - weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004; 104: 634–41.
- Pfreundschuh M, Kloess M, Zeynalova S et al. Six vs. eight cycles of di - weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the completed RICOVER-60 trial of the German high - grfde njn - Hodgkin’s lymphoma study group (DSHNHL). Blood; ASH Annual Meeting Abstracts, 2006: 108: Abstract 205.
Supplementary files
